New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:44 EDTAMGN, PFE, MRK, INCYMerck signs three clinical collaboration agreements to evaluate MK-3475
Merck (MRK) announced it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen (AMGN), Incyte (INCY) and Pfizer (PFE) to evaluate novel combination regimens with MK-3475, Merck's investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed.
News For MRK;AMGN;INCY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 23, 2015
07:36 EDTPFEPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
07:17 EDTMRKAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
13:03 EDTPFEPfizer says oral tofacitinib meets primary endpoint in Phase 3 trials
Subscribe for More Information
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:55 EDTPFEAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:41 EDTMRK, PFE, AMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
March 17, 2015
16:11 EDTAMGNAmgen to present 10 abstracts from dermatology portfolio
Subscribe for More Information
05:32 EDTINCYIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
March 16, 2015
15:33 EDTMRKMerck says study shows VYTORIN reduced CV events more than simvastatin alone
Subscribe for More Information
08:52 EDTAMGNAmgen to hold a conference call
Conference call to provide an update from the 73rd Annual Meeting of AAD will be held on March 23 at 3 pm. Webcast Link
08:35 EDTAMGNAmgen to hold a conference call
Executive Vice President of R&D, Sean Harper, discusses Amgen's cardiovascular program, including the Repatha data currently being presented at the American College of Cardiology's Scientific Session & Expo, on a conference call to be held on March 16 at 4 pm. Webcast Link
08:23 EDTAMGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
06:57 EDTAMGNAmgen clinical data very positive, says RBC Capital
Subscribe for More Information
06:40 EDTPFE, AMGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:11 EDTAMGNAmgen publishes safety analysis of Repatha in New England Journal of Medicine
Subscribe for More Information
12:53 EDTAMGNAmgen announces new data from study of Repatha in combination with statins
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use